Prolonged inhibition of interleukin-6 mediated signaling
AssigneeAblynx N.V.
InventorsJosefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
Life of this patent
Estimating the term…
Loading patent…
AssigneeAblynx N.V.
InventorsJosefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
Estimating the term…
Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
A method for inhibiting IL-6 mediated signaling in a subject comprising administering to the subject a polypeptide that specifically binds IL-6R, wherein the amount of the polypeptide administered is effective:
A polypeptide that specifically binds IL-6R for treatment of diseases and/or disorders associated with IL-6 mediated signaling, wherein the amount of the polypeptide administered is effective
Dependencies are inferred from the claim text.